TEAD4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1158367	0.46	8/20
SCHEMBL622814	0.46	6/20
SCHEMBL1887127	0.66	5/20
SCHEMBL1887157	0.58	5/20
SCHEMBL1878090	0.56	5/20
SCHEMBL1888843	0.59	4/20
SCHEMBL1686913	0.40	4/20
SCHEMBL1888399	0.52	3/20
SCHEMBL1445091	0.42	3/20
Pirlindole (SCHEMBL373564)	1.00	2/20
Pirlindole (SCHEMBL1649683)	0.95	2/20
Flufenamic Acid (SCHEMBL17497)	0.71	2/20
Niflumic Acid (SCHEMBL840856)	0.70	2/20
SCHEMBL1526967	0.60	2/20
Pirlindole (SCHEMBL466384)	0.59	2/20
SCHEMBL1688342	0.55	2/20
SCHEMBL361714	0.51	2/20
SCHEMBL1875327	0.48	2/20
SCHEMBL787451	0.47	2/20
SCHEMBL1882242	0.46	2/20

Clinical trials — most relevant to TEAD4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention	PHASE2	NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Green Tea Anticancer Mechanisms in Smokers	nan	COMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
Family Resilience Initiative Research Program	nan	UNKNOWN
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies	nan	RECRUITING
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Sorting and Expression Profiling of Airway Cells From Humans (The SEARCH Study)	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Epigenetic Testing for Breast Cancer Risk Stratification	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a TEAD4 binder may also engage these)

Protein	Name	Similarity
P70210	—	1.000	P70210 →
Q62296	—	1.000	Q62296 →
TEAD3	Transcriptional enhancer factor TEF-5	1.000	landscape →
P30051	—	1.000	P30051 →
Q90701	—	1.000	Q90701 →
P48984	—	0.999	P48984 →
TEAD1	Transcriptional enhancer factor TEF-1	0.999	landscape →
P30052	—	0.997	P30052 →
P48301	—	0.997	P48301 →
TEAD2	Transcriptional enhancer factor TEF-4	0.995	landscape →
Q19849	—	0.993	Q19849 →
Q9XSK8	—	0.989	Q9XSK8 →
Q02225	—	0.989	Q02225 →
Q9JHD2	—	0.988	Q9JHD2 →
Q9JJP2	—	0.988	Q9JJP2 →
P70662	—	0.988	P70662 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.988	landscape →
KAT2B	Histone acetyltransferase KAT2B	0.988	landscape →
Q8TE85	—	0.988	Q8TE85 →
Q5FWH3	—	0.987	Q5FWH3 →
O43439	—	0.987	O43439 →
Q60520	—	0.987	Q60520 →
Q9Z136	—	0.987	Q9Z136 →
KAT2A	Histone acetyltransferase KAT2A	0.987	landscape →
A0M8T5	—	0.987	A0M8T5 →
Q9TU15	—	0.987	Q9TU15 →
Q9EP53	—	0.987	Q9EP53 →
Q09YK4	—	0.987	Q09YK4 →
Q2IBA2	—	0.987	Q2IBA2 →
A5D794	—	0.986	A5D794 →